Table of Contents
More than 65% of approved medicines work by binding to proteins on the surface of human cells, yet the major biological databases disagree on which proteins are actually there. The Deliverome Project, an open research initiative, used artificial intelligence to review the published evidence and build a map of the human surfaceome, the full set of cell surface proteins.
The map flags 1,108 candidate proteins that are missing from all five major reference databases but are supported by published studies. The findings were posted in October 2026 as a preprint on bioRxiv, so they have not yet been peer reviewed, and the proteins are candidates rather than confirmed targets.
Databases that disagree
The team compared five databases: UniProt, GO CC, the Human Protein Atlas, the Cell Surface Protein Atlas and SURFY. Together they list 5,546 surface proteins, but all five agree on only 188, according to the Hertz Foundation.
How the tool works
Co-founders Becca Carlson and Bobby Hollingsworth built an AI agent using the Claude Sonnet 4.6 model. The agent reviews the scientific literature to determine whether a protein sits on the cell surface.
On SurfaceBench, a hand-labeled collection consisting of 147 proteins, the agent achieved a 95.7% classification accuracy, whereas UniProt, which stood out as the top-performing database, reached roughly 90%.
An example: the KLK2 protein
All five databases classify the protein KLK2 as absent from the cell surface. However, research has found a membrane-anchored form enriched in prostate cancer, and an experimental therapy targeting it is in Phase 3 trials. Deliverome classifies KLK2 as able to appear on the surface under certain conditions.
An open resource
The map is free to explore in Open View, an interactive tool that showcases each protein next to its corresponding research. Additionally, the initiative provides a public API alongside open-source code.
“My hope is that this will help people develop drugs that are more diverse and serve more patients and more indications,” said Carlson, a 2017 Hertz Fellow and the project’s co-CEO.
Deliverome launched on May 27, 2026, backed by $5 million in seed capital originating from the Astera Institute. Operating as a Focused Research Organization, it utilizes a framework tailored to roll out public research instruments inside roughly half a decade. Investigators affiliated with Coral Biosciences additionally contributed as co-authors on the preprint.
References
- Deliverome Project and Coral Biosciences: “The accessible human surfaceome”, bioRxiv, October 2026 (preprint).
- Hertz Foundation: “Hertz Fellow Becca Carlson Uses AI to Identify New Drug Targets on Human Cells”, October 22, 2026.
- Deliverome: Open View, an interactive map of the accessible surfaceome.
- Institute for Progress: “The Deliverome Project”, May 27, 2026.



